Data gathered: March 6
AI Stock Analysis - Iovance Biotherapeutics (IOVA)
Analysis generated March 1, 2025. Powered by Chat GPT.
Iovance Biotherapeutics, Inc. is a biotechnology company that focuses on the development and commercialization of innovative cancer immunotherapies. The company's primary emphasis is on Tumor-Infiltrating Lymphocyte (TIL) therapy, which leverages the body’s immune system to target and eradicate cancer cells. Iovance is deeply invested in research and development, aiming to bring pioneering treatments to market that address unmet medical needs in oncology.
Stock Alerts - Iovance Biotherapeutics (IOVA)
 |
Iovance Biotherapeutics | March 5 Price is up by 5.4% in the last 24h. |
|
Iovance Biotherapeutics | March 4 Price is down by -5.5% in the last 24h. |
|
Iovance Biotherapeutics | March 3 Price is down by -5.6% in the last 24h. |
|
Iovance Biotherapeutics | February 28 Price is down by -26.8% in the last 24h. |
Alternative Data for Iovance Biotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 124 | Sign up | Sign up | Sign up |
| Sentiment | 95 | Sign up | Sign up | Sign up |
| Webpage traffic | 26,000 | Sign up | Sign up | Sign up |
| Employee Rating | 60 | Sign up | Sign up | Sign up |
| Google Trends | 12 | Sign up | Sign up | Sign up |
| Patents | 191 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 66 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 14,700 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,632 | Sign up | Sign up | Sign up |
| Twitter Mentions | 92 | Sign up | Sign up | Sign up |
| News Mentions | 2 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 50 | Sign up | Sign up | Sign up |
| Linkedin Employees | 821 | Sign up | Sign up | Sign up |
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
| Price | $4.05 |
| Target Price | Sign up |
| Volume | 11,210,000 |
| Market Cap | $1.29B |
| Year Range | $3.92 - $12.28 |
| Dividend Yield | 0% |
| Analyst Rating | 90% buy |
| Industry | Biotechnology |
In the news
 |
Chardan Capital Issues Pessimistic Forecast for Iovance Biotherapeutics (NASDAQ:IOVA) Stock PriceMarch 5 - ETF Daily News |
 |
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Cut to $19.00 by Analysts at The Goldman Sachs GroupMarch 4 - ETF Daily News |
|
Iovance Biotherapeutics (NASDAQ:IOVA) Given New $15.00 Price Target at Truist FinancialMarch 4 - ETF Daily News |
|
What is HC Wainwright’s Estimate for IOVA Q1 Earnings?March 2 - ETF Daily News |
|
Traders Purchase Large Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)February 28 - ETF Daily News |
 |
Iovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call TranscriptFebruary 27 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 59M | 40M | 19M | -84M | -84M | -0.280 |
| Q2 '24 | 31M | 31M | -260,000 | -97M | -96M | -0.340 |
| Q1 '24 | 810,000 | 7.3M | -6.5M | -113M | -113M | -0.420 |
| Q4 '23 | 590,000 | 4.4M | -3.8M | -116M | -117M | -0.450 |
| Q3 '23 | 470,000 | 4.3M | -3.9M | -114M | -114M | -0.460 |
Insider Transactions View All
| Maynard Ryan D filed to sell 7,500 shares at $10.1. November 14 '24 |
| Dukes Iain D. filed to buy 54,000 shares at $9.2. February 20 '24 |
| MCPEAK MERRILL A filed to buy 320,150 shares at $9.2. February 20 '24 |
| Rothbaum Wayne P. filed to buy 28,067,333 shares at $9.2. February 20 '24 |
| MCPEAK MERRILL A filed to buy 248,633 shares at $5.6. September 19 '23 |
Similar companies
Read more about Iovance Biotherapeutics (IOVA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Iovance Biotherapeutics?
The Market Cap of Iovance Biotherapeutics is $1.29B.
What is the current stock price of Iovance Biotherapeutics?
Currently, the price of one share of Iovance Biotherapeutics stock is $4.05.
How can I analyze the IOVA stock price chart for investment decisions?
The IOVA stock price chart above provides a comprehensive visual representation of Iovance Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Iovance Biotherapeutics shares. Our platform offers an up-to-date IOVA stock price chart, along with technical data analysis and alternative data insights.
Does IOVA offer dividends to its shareholders?
As of our latest update, Iovance Biotherapeutics (IOVA) does not offer dividends to its shareholders. Investors interested in Iovance Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Iovance Biotherapeutics?
Some of the similar stocks of Iovance Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.